Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen Vaccines in Pancreatic Cancer Prior to Surgery
NCT05111353Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of optimized neoantigen synthetic long peptide vaccine in pancreatic cancer (PC) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Adverse Events. Started Dec 2022; status: active, not recruiting.
02
Drugs
optimized neoantigen synthetic long peptide vaccine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05111353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111353.